Last Price$272.70.1%
Market Cap$19.4B
LTM Cash & Cash Equivalents
$953.4M
YoY Growth
+46.5%
3Y CAGR
+6.4%
5Y CAGR
+20.4%
Stock quality & Intrinsic value
8/10
50.7% overvalued
Insulet Corporation Cash & Cash Equivalents
Annual
Quarterly
LTM
Crunching data... Almost there!
| Dec'04 | Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Cash Equivalents | $24.0M | $7,660.0K | $33.2M | $94.6M | $56.7M | $128.0M | $113.3M | $94.0M | $57.3M | $149.7M | $151.2M | $122.7M | $298.6M | $440.1M | $288.9M | $376.1M | $947.6M | $791.6M | $674.7M | $704.2M |
Overvalued or undervalued?
Check the intrinsic value for PODD
and see if it's the right time to invest.
Insulet Corporation (PODD) Cash & Cash Equivalents comparison analysis
General
LTM Cash & Cash Equivalents
Growth
Company name
YoY growth
3Y CAGR
5Y CAGR
Insulet CorporationPODD
$953.4M
46.5%
6.4%
20.4%
Median Peer Set
$1,141.9M
10.9%
(4.9%)
8.7%
Abbott LaboratoriesABT
$7,616.0M
10.4%
(8.1%)
14.6%
Edwards Lifesciences CorporationEW
$3,676.4M
160.7%
34.6%
25.4%
Stryker CorporationSYK
$3,652.0M
22.9%
7.4%
(3.4%)
Koninklijke Philips N.V.PHG
$2,486.2M
20.5%
1.4%
11.0%
Medtronic plcMDT
$1,240.0M
(23.6%)
(29.1%)
(19.7%)
Align Technology, Inc.ALGN
$1,043.9M
11.4%
(1.7%)
13.7%
DexCom, Inc.DXCM
$606.1M
7.0%
(16.8%)
6.3%
Zimmer Biomet Holdings, Inc.ZBH
$525.5M
26.4%
11.6%
(3.2%)
Boston Scientific CorporationBSX
$414.0M
(52.1%)
(40.1%)
13.8%
STERIS plcSTE
$155.2M
(20.7%)
(24.4%)
(4.9%)
PODD key stats
USD
Millions
Billions
Annual
Quarterly
Trailing
Key stats
Income statement
Balance sheet
Cash Flow Statement
Valuation
Ratios
Per share
Per employee
Dividends & Yields
| Dec'04 | Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
% growth | 0.0 0.0% | 0.1 0.0% | 3.7 7,226.0% | 13.4 265.1% | 36.1 169.7% | 66.0 83.1% | 97.0 46.8% | 152.3 57.0% | 211.4 38.8% | 247.1 16.9% | 288.7 16.9% | 263.9 (8.6%) | 367.0 39.1% | 463.8 26.4% | 563.8 21.6% | 738.2 30.9% | 904.4 22.5% | 1,098.8 21.5% | 1,305.3 18.8% | 1,697.1 30.0% |
| Cost of Goods Sold (COGS) | 0.0 | 1.5 | 15.7 | 25.7 | 40.6 | 47.7 | 53.2 | 85.5 | 119.0 | 134.7 | 145.4 | 130.6 | 155.9 | 186.6 | 193.7 | 257.9 | 322.1 | 346.7 | 499.7 | 537.2 |
% margin | 0.0 0.0% | (1.5) (2,960.0%) | (12.0) (327.5%) | (12.4) (92.4%) | (4.6) (12.7%) | 18.3 27.7% | 43.7 45.1% | 66.7 43.8% | 92.3 43.7% | 112.4 45.5% | 143.3 49.6% | 133.3 50.5% | 211.1 57.5% | 277.2 59.8% | 370.2 65.7% | 480.3 65.1% | 582.3 64.4% | 752.1 68.4% | 805.6 61.7% | 1,159.9 68.3% |
| Operating Expenses | 14.2 | 20.0 | 22.6 | 41.5 | 84.8 | 77.7 | 77.9 | 109.2 | 128.3 | 141.5 | 155.6 | 182.0 | 221.8 | 284.6 | 342.7 | 430.3 | 530.8 | 626.1 | 768.0 | 939.9 |
| Research & Development Expenses (R&D) | 9.0 | 10.8 | 8.1 | 10.4 | 13.1 | 13.2 | 16.6 | 21.9 | 24.4 | 21.8 | 27.9 | 43.2 | 55.7 | 74.5 | 88.6 | 129.7 | 146.8 | 160.1 | 180.2 | 205.0 |
| Selling, General & Administrative Expenses (SG&A) | 5.1 | 9.3 | 14.6 | 30.1 | 63.5 | 64.4 | 61.4 | 87.3 | 103.9 | 119.8 | 127.7 | 138.8 | 166.1 | 210.1 | 254.1 | 300.6 | 384.0 | 466.0 | 587.8 | 734.9 |
% margin | (14.2) 0.0% | (21.5) (43,010.0%) | (34.6) (945.8%) | (53.8) (402.6%) | (89.3) (247.8%) | (59.4) (89.9%) | (38.6) (39.8%) | (42.5) (27.9%) | (36.0) (17.0%) | (29.1) (11.8%) | (12.3) (4.3%) | (48.7) (18.5%) | (10.7) (2.9%) | (7.4) (1.6%) | 27.4 4.9% | 22.1 3.0% | (0.6) (0.1%) | 66.7 6.1% | (26.7) (2.0%) | 220.0 13.0% |
| Interest Income | 0.0 | 0.0 | 0.0 | 0.0 | 1.8 | 0.2 | 0.2 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.8 | 2.6 | 6.7 | 7.8 | 3.0 | 0.5 | 9.8 | 28.6 |
| Interest Expense | 0.0 | 0.0 | 0.0 | 0.0 | 7.2 | 20.2 | 22.7 | 14.7 | 15.8 | 17.2 | 14.7 | 12.7 | 14.4 | 19.2 | 22.2 | 26.8 | 45.1 | 61.2 | 26.7 | 36.2 |
| Pre-tax Income | 0.0 | 0.0 | (35.5) | (53.5) | (92.8) | (79.5) | (61.2) | (57.0) | (51.7) | (44.9) | (51.4) | (61.4) | (26.8) | (26.6) | 5.2 | 14.5 | 9.7 | 20.5 | 9.8 | 214.6 |
% effective tax rate | (0.3) 0.0% | 0.1 0.0% | 1.3 (3.7%) | (0.3) 0.6% | 3.4 (3.7%) | (5.2) 6.6% | 21.9 (35.8%) | 0.1 (0.2%) | 0.2 (0.4%) | 0.1 (0.2%) | 0.1 (0.3%) | 0.2 (0.3%) | 0.4 (1.5%) | 0.3 (1.0%) | 1.9 37.0% | 2.9 20.0% | 2.9 29.9% | 3.7 18.0% | 5.2 53.1% | 8.3 3.9% |
% margin | (13.8) 0.0% | (21.6) (43,272.0%) | (36.0) (981.4%) | (53.5) (400.4%) | (92.8) (257.3%) | (79.5) (120.5%) | (61.2) (63.1%) | (57.2) (37.5%) | (51.9) (24.5%) | (45.0) (18.2%) | (51.5) (17.8%) | (73.5) (27.9%) | (28.9) (7.9%) | (26.8) (5.8%) | 3.3 0.6% | 11.6 1.6% | 6.8 0.8% | 16.8 1.5% | 4.6 0.4% | 206.3 12.2% |
| EPS | (47.64) | (70.95) | (99.10) | (3.21) | (3.36) | (2.68) | (1.54) | (1.22) | (1.08) | (0.83) | (0.93) | (1.29) | (0.51) | (0.46) | 0.06 | 0.19 | 0.11 | 0.25 | 0.07 | 2.96 |
| Diluted EPS | (47.64) | (70.95) | (39.19) | (3.21) | (3.36) | (2.68) | (1.54) | (1.22) | (1.08) | (0.83) | (0.93) | (1.29) | (0.50) | (0.46) | 0.05 | 0.19 | 0.10 | 0.25 | 0.07 | 2.80 |
% margin | (13.5) 0.0% | (20.3) (40,538.0%) | (32.0) (873.7%) | (48.9) (365.9%) | (81.2) (225.1%) | (53.9) (81.6%) | (33.4) (34.4%) | (35.8) (23.5%) | (24.8) (11.7%) | (16.2) (6.5%) | (24.4) (8.5%) | (36.3) (13.7%) | 1.3 0.3% | 6.5 1.4% | 49.8 8.8% | 77.0 10.4% | 110.3 12.2% | 139.6 12.7% | 109.5 8.4% | 323.6 19.1% |
Discover more Stock Ideas
Undervalued stocks right now
Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 32.1%
S&P Outperformance 19.1%
Next 3M Predicted Return 20.3%
Undervalued growth stocks
Discover the top 20 best undervalued large-cap growth stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 35.3%
S&P Outperformance 22.3%
Next 3M Predicted Return 26.8%
Undervalued dividend stocks
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.
3M Return 28.4%
S&P Outperformance 15.4%
Next 3M Predicted Return 16.9%
FAQ
1) What is Insulet Corporation's Cash & Cash Equivalents?
As of today, Insulet Corporation's last 12-month Cash & Cash Equivalents is $953.4M, based on the financial report for Dec 31, 2024 (Q4’2024).
2) What is Insulet Corporation's Cash & Cash Equivalents growth rate?
Over the last year, Insulet Corporation's Cash & Cash Equivalents growth was 46.5%. The average annual Cash & Cash Equivalents growth rates for Insulet Corporation have been 3.0% over the past three years, 20.4% over the past five years.
3) Is Insulet Corporation's Cash & Cash Equivalents growth rate Good?
Over the last year, Insulet Corporation's Cash & Cash Equivalents growth was 46.5%, which is higher than industry growth of (0.1%). It indicates that Insulet Corporation's Cash & Cash Equivalents growth is Good.